Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Angiolink Corporation

Request full access

Angiolink privately held medical device company focused on developing innovative wound closure solutions for vascular procedures

Taunton, United StatesFounded 1999Health Tech & Medtech

About Angiolink Corporation

Angiolink Corporation, established in 1999, was a privately held medical device company that focused on developing wound closure solutions for vascular procedures. Based in Taunton, Massachusetts, the company identified a critical need for safer and more efficient methods to close femoral artery access sites following catheter-based interventions like diagnostic angiography and stenting. This led to the development of its flagship product, the EVS™ (Expanding Vascular Stapling) Vascular Closure System.

The EVS system was engineered to provide an extraluminal closure of the femoral artery by applying a biocompatible titanium staple. This mechanical closure was designed to approximate the arteriotomy edges, promoting natural healing and significantly reducing the time to hemostasis and patient ambulation compared to traditional manual compression methods. The device consisted of a single-use, trigger-activated deployment tool and the staple itself, which remained sterile within the housing until application, minimizing the risk of contamination. The system was intended for use by physicians to close arterial punctures from 6F to 8F procedural sheaths.

Angiolink secured significant financial backing from investors including BioVentures Investors, JHK Investments, and IDP Investments, raising a total of $27.8 million over several funding rounds. A pivotal moment for the company occurred in late 2004 when it received FDA pre-market approval for the EVS system. Almost simultaneously, in November 2004, Angiolink was acquired by Medtronic, a global leader in medical technology. At the time of the acquisition, Angiolink employed 15 people and was poised to enter a vascular closure market estimated to be worth around $500 million. The acquisition integrated Angiolink's operations into Medtronic's Danvers, Massachusetts facility, leveraging Medtronic's scale to bring the EVS technology to a wider global market.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
17.0/100
Industry
Health
Sub-industry
Medical Devices
Sector
Surgery, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2003 $14M $54M Bioventures Investors · Boston Financial & Equity Corporation · IDP Industrial Development Partners —
SERIES A✓Equity / VC Sep 2002 $11M $42M Boston Financial & Equity Corporation · Bioventures Investors —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Angiolink Corporation website traffic

Latest recorded traffic for Angiolink Corporation is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Angiolink Corporation in the Taunton ecosystem

Live from Dealroom

The Angiolink Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Bioventures Investors
  • Boston Financial & Equity Corporation
  • IDP Industrial Development Partners
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Taunton HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Angiolink Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Angiolink Corporation’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.